Coherus Biosciences | CHRS - Debt


Coherus Biosciences reported $294.92M in Debt for its fiscal quarter ending in March of 2025.





Debt Change Date
AbbVie USD 72.86B 5.36B Mar/2026
Acadia Pharmaceuticals USD 50.79M 1.39M Mar/2026
Akebia Therapeutics USD 46.51M 7.82M Mar/2025
ALKERMES USD 1.58B 1.51B Mar/2026
Alnylam Pharmaceuticals USD 1.27B 5.33M Mar/2026
Amarin USD 0 0 Mar/2025
Amgen USD 57.32B 2.72B Mar/2026
Baxter International USD 9.69B 93M Mar/2026
Biogen USD 8.09B 1.53B Jun/2026
BioMarin Pharmaceutical USD 1.44B 833.74M Mar/2026
Bristol-Myers Squibb USD 46.43B 711M Mar/2026
Coherus Biosciences USD 294.92M 1.25M Mar/2025
Eli Lilly USD 43.37B 867M Mar/2026
Fujifilm JPY 1.03T 104.2B Mar/2026
Gilead Sciences USD 22.17B 2.76B Mar/2026
Ironwood Pharmaceuticals USD 583.99M 14.83M Dec/2024
Merck USD 49.12B 222M Mar/2026
Myriad Genetics USD 59.3M 19.7M Mar/2025
Pacira USD 363.12M 4.53M Jun/2026
Perrigo USD 3.63B 7.7M Mar/2026
Pfizer USD 63.19B 536M Jun/2026
PTC Therapeutics USD 286.94M 2.42B Mar/2026
Regeneron Pharmaceuticals USD 2.71B 400K Jun/2026
Sarepta Therapeutics USD 1.04B 3.08M Mar/2026
Teva Pharmaceutical Industries USD 16.91B 187M Mar/2026
Vertex Pharmaceuticals USD 1.98B 8.9M Jun/2026
Xencor USD 175.16M 12.58M Mar/2026
Zoetis USD 9.24B 0 Mar/2026